Santarus (SNTS) in Focus: Stock Advances 6.2% - Analyst Blog
) was a big mover last session, as the company saw its shares
rise by over 6% on the day. The move came on the back of solid
volume too, as far more shares changed hands than in a normal
session. This price movement is a reversal for this biotechnology
company, as the stock moved down more than 5% over the past
one-month time period.
The company has seen 3 positive revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting there could be more solid trading down the road for SNTS. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Santarus currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%.
Some better performing biotechnology stocks include Elan Corporation, plc ( ELN ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Lannett Company, Inc. ( LCI ). All these carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ELAN CP PLC ADR (ELN): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
SANTARUS INC (SNTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research